Buprenorphine, Naloxone Drug Combination

"Buprenorphine, Naloxone Drug Combination" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A pharmaceutical preparation that combines buprenorphine, an OPIOID ANALGESIC with naloxone, a NARCOTIC ANTAGONIST to reduce the potential for NARCOTIC DEPENDENCE in the treatment of pain. It may also be used for OPIATE SUBSTITUTION THERAPY.

Descriptor ID	D000069479
MeSH Number(s)	D03.132.577.249.150.500 D03.132.577.249.706.275 D03.605.497.150.500 D03.605.497.750.275 D03.633.400.686.150.500 D03.633.400.686.750.275 D04.615.723.795.150.500 D04.615.723.795.706.275 D26.310.352
Concept/Terms	Buprenorphine, Naloxone Drug Combination Buprenorphine, Naloxone Drug Combination Buprenorphine-Naloxone Drug Combination Combination, Buprenorphine-Naloxone Drug Drug Combination, Buprenorphine-Naloxone Buprenorphine-Naloxone Buprenorphine Naloxone Naloxone, Buprenorphine Buprenorphine-Naloxone Combination Buprenorphine Naloxone Combination Combination, Buprenorphine-Naloxone Buprenorphine Naloxone Drug Combination Suboxone Suboxone

Below are MeSH descriptors whose meaning is more general than "Buprenorphine, Naloxone Drug Combination".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Alkaloids [D03.132]
Opiate Alkaloids [D03.132.577]
Morphinans [D03.132.577.249]
Buprenorphine [D03.132.577.249.150]
Buprenorphine, Naloxone Drug Combination [D03.132.577.249.150.500]
Naloxone [D03.132.577.249.706]
Buprenorphine, Naloxone Drug Combination [D03.132.577.249.706.275]
Heterocyclic Compounds, Bridged-Ring [D03.605]
Morphinans [D03.605.497]
Buprenorphine [D03.605.497.150]
Buprenorphine, Naloxone Drug Combination [D03.605.497.150.500]
Naloxone [D03.605.497.750]
Buprenorphine, Naloxone Drug Combination [D03.605.497.750.275]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 4 or More Rings [D03.633.400]
Morphinans [D03.633.400.686]
Buprenorphine [D03.633.400.686.150]
Buprenorphine, Naloxone Drug Combination [D03.633.400.686.150.500]
Naloxone [D03.633.400.686.750]
Buprenorphine, Naloxone Drug Combination [D03.633.400.686.750.275]
Polycyclic Compounds [D04]
Polycyclic Aromatic Hydrocarbons [D04.615]
Phenanthrenes [D04.615.723]
Morphinans [D04.615.723.795]
Buprenorphine [D04.615.723.795.150]
Buprenorphine, Naloxone Drug Combination [D04.615.723.795.150.500]
Naloxone [D04.615.723.795.706]
Buprenorphine, Naloxone Drug Combination [D04.615.723.795.706.275]
Pharmaceutical Preparations [D26]
Drug Combinations [D26.310]
Buprenorphine, Naloxone Drug Combination [D26.310.352]

Below are MeSH descriptors whose meaning is related to "Buprenorphine, Naloxone Drug Combination".

Below are MeSH descriptors whose meaning is more specific than "Buprenorphine, Naloxone Drug Combination".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Buprenorphine, Naloxone Drug Combination" by people in this website by year, and whether "Buprenorphine, Naloxone Drug Combination" was a major or minor topic of these publications.

Bar chart showing 18 publications over 12 distinct years, with a maximum of 3 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2009	0	1	1
2012	0	2	2
2013	0	1	1
2015	1	0	1
2016	1	0	1
2017	1	0	1
2018	1	0	1
2019	2	0	2
2021	0	3	3
2022	0	2	2
2023	0	1	1
2024	1	1	2

Below are the most recent publications written about "Buprenorphine, Naloxone Drug Combination" by people in Profiles.

Christine PJ, Lodi S, Hsu HE, Bovell-Ammon B, Yan S, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz J, Walley AY, Larochelle MR. Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder. Addiction. 2024 07; 119(7):1313-1321.

View in: PubMed
Feeney ME, Law AC, Walkey AJ, Bosch NA. Variation in Use of Medications for Opioid Use Disorder in Critically Ill Patients Across the United States. Crit Care Med. 2024 Jul 01; 52(7):e365-e375.

View in: PubMed
Pepin MD, Joseph JK, Chapman BP, McAuliffe C, O'Donnell LK, Marano RL, Carreiro SP, Garcia EJ, Silk H, Babu KM. A mobile addiction service for community-based overdose prevention. Front Public Health. 2023; 11:1154813.

View in: PubMed
Wilson SC, Shaffer JA, Wachholtz AB. Distress Tolerance in the Comorbid Chronic Pain and Opioid Use Disorder Population. J Addict Med. 2023 May-Jun 01; 17(3):e164-e171.

View in: PubMed
Randall A, Hull I, Martin SA. Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation. J Addict Med. 2023 Mar-Apr 01; 17(2):237-240.

View in: PubMed
Zhu Y, Mooney LJ, Yoo C, Evans EA, Kelleghan A, Saxon AJ, Curtis ME, Hser YI. Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone. Drug Alcohol Depend. 2021 11 01; 228:108996.

View in: PubMed
Shirk SD, Ameral V, Kraus SW, Houchins J, Kelly M, Pugh K, Reilly E, Desai N. Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A?Retrospective Chart Review. J Dual Diagn. 2021 Jul-Sep; 17(3):207-215.

View in: PubMed
Hser YI, Zhu Y, Fei Z, Mooney LJ, Evans EA, Kelleghan A, Matthews A, Yoo C, Saxon AJ. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. Addiction. 2022 01; 117(1):151-161.

View in: PubMed
Evans EA, Yoo C, Huang D, Saxon AJ, Hser YI. Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2?years: Results from a multisite randomized trial of adults with opioid use disorder. J Subst Abuse Treat. 2019 11; 106:19-28.

View in: PubMed
Evans EA, Zhu Y, Yoo C, Huang D, Hser YI. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. Addiction. 2019 08; 114(8):1396-1404.

View in: PubMed

People

Explore

Similar Concepts

Top Journals